Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

0.4723 +0.0069 (+1.48%)
Streaming Delayed Price Updated: 3:22 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Provides Business and Operational Update
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Announces Pricing of $42.0 Million Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Announces Proposed Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.